Number of Shares and Voting Rights of ADOCIA as of October 31st, 2021
November 19 2021 - 11:00AM
Business Wire
Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French
« Code de Commerce » and article 223-16 of the French stock-market
authorities (Autorité des Marchés Financiers, or “AMF”) charter
ADOCIA SA, a French société anonyme (corporation), 115, avenue
Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC)
(Paris:ADOC) a clinical stage biopharmaceutical company focused on
treatment of diabetes, obesity and metabolic diseases with
innovative formulations of approved proteins, releases its total
number of outstanding shares as well as its voting rights as of
October 31st, 2021.
Month
Date
Total number of outstanding
shares
Total number of theoretical
voting rights (1)
Total number of exercisable
voting rights (2)
October
10/31/2021
7 137 521
9 909 064
9 871 140
(1) The total number of theoretical voting rights (or “gross”
voting rights) is used as the basis for calculating the crossing of
shareholding thresholds. In accordance with Article 223-11 of the
AMF General Regulation, this number is calculated on the basis of
all shares to which voting rights are attached, including shares
whose voting rights have been suspended.
(2) The total number of exercisable voting rights (or” net”
voting rights) is calculated without taking into account the shares
with suspended voting rights, in this case, shares held by the
Company in the context of a liquidity agreement.
About Adocia
Adocia is a clinical-stage biotechnology company that
specializes in the development of innovative formulations of
therapeutic proteins and peptides for the treatment of diabetes and
metabolic diseases. In the diabetes field, Adocia’s portfolio of
injectable treatments is among the largest and most differentiated
of the industry, featuring six clinical-stage products and several
pre-clinical products. The proprietary BioChaperone® technological
platform is designed to enhance the effectiveness and/or safety of
therapeutic proteins while making them easier for patients to use.
Adocia customizes BioChaperone® to each protein for a given
application.
Adocia’s clinical pipeline includes five novel insulin
formulations for the treatment of diabetes: two ultra-rapid
formulations of insulin analog lispro (BioChaperone® Lispro U100
and U200), a combination of basal insulin glargine and rapid acting
insulin lispro (BioChaperone® Combo) and two combinations of a
prandial insulin with amylin analog pramlintide (M1Pram and
BioChaperone® LisPram). The clinical pipeline also includes an
aqueous formulation of human glucagon (BioChaperone® Glucagon) for
the treatment of hypoglycemia.
Adocia preclinical pipeline includes bi-hormonal combinations
for diabetes treatment: a combination of rapid acting insulin
analogs and pramlintide (BioChaperone® AsPram), a combination of
insulin glargine with GLP-1 receptor agonists (BioChaperone®
Glargine Liraglutide). In addition, there are two bi-hormonal
products for the treatment of obesity: a combination of glucagon
and exenatide (BioChaperone® GluExe) and a combination of
pramlintide and exenatide (PramExe).
Adocia recently added a preclinical program to its pipeline with
a cell therapy initiative focused on the development of a hydrogel
scaffold for use in people with type 1 diabetes. The first patent
application supporting this program has been filed.
Disclaimer This press release
contains certain forward-looking statements concerning Adocia and
its business. Such forward-looking statements are based on
assumptions that Adocia considers as being reasonable. However,
there can be no guarantee that the estimates contained in such
forward-looking statements will be achieved, as such estimates are
subject to numerous risks including those which are set forth in
the “Risk Factors” section of the Universal Registration Document
that was filed with the French Autorité des marchés financiers on
April 20, 2021 (a copy of which is available at www.adocia.com), in
particular uncertainties that are linked to research and
development, future clinical data, analyses, and the evolution of
the economic context, the financial markets and the markets in
which Adocia operates. The forward-looking statements contained in
this press release are also subject to risks not yet known to
Adocia or not considered as material by Adocia as of this day. The
occurrence of all or part of such risks could cause that actual
results, financial conditions, performances, or achievements of
Adocia be materially different from those mentioned in the
forward-looking statements. This press release and the information
contained herein do not constitute an offer to sell or the
solicitation of an offer to buy Adocia’s shares in any
jurisdiction.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211119005562/en/
Adocia Gérard Soula CEO contactinvestisseurs@adocia.com
Ph: +33 4 72 610 610 www.adocia.com
MC Services AG Adocia Press Relations Europe Raimund
Gabriel Managing Partner adocia@mc-services.eu Ph: +49 89 210
228 0
The Ruth Group Adocia Investor Relations USA Brett
Mermelstein Senior Account Executive
bmermelstein@theruthgroup.com Ph.: +1 267 639 0721
Adocia (EU:ADOC)
Historical Stock Chart
From Dec 2024 to Jan 2025
Adocia (EU:ADOC)
Historical Stock Chart
From Jan 2024 to Jan 2025
